ROCKVILLE, MD – Tasly Pharmaceuticals Co. Ltd. of China and Tasly Pharmaceuticals, Inc. of USA, a global leader in pharmaceuticals, biologics and nutraceuticals, announced that its three-herb composition drug T89 (Dantonic), has been shown in a Phase 3 global clinical trial to improve Treadmill exercise duration (TED) and more effectively reduce the frequency of chronic stable angina with few adverse reactions.
The findings were presented on March 12, 2018 by Tasly Pharmaceuticals CEO/President Henry Sun, PhD, and colleagues, to the American College of Cardiologists at the 67th Annual Scientific Session (ACC 2018 conference) in Orlando, Florida.
Tasly T89 is the world’s first compound Chinese herbal drug to have passed U.S. Food and Drug Administration regulated multi-center phase 3 clinical trials and is on a path to open the door for Traditional Chinese Medicine (TCM) globalization.
The results unveiled by Dr. Sun showed that the T89 composition drug, Dantonic, improves blood circulation and energy metabolism and reduces blood viscosity, the measurement of the thickness and stickiness of blood, in patients with chronic stable angina compared to other processes. It also demonstrates excellent therapeutic benefits and safety profiles for patients with chronic stable angina, a form of chest pain when the heart is working very hard and needs more oxygen, Dr. Sun’s presentation indicates.
The results showed improved clinical outcomes in comparison to existing anti-anginal drugs (CAAD), such as beta-blockers, Ca++channel blockers, and nitrates that only target the coronary artery, Dr. Sun said. “There were no apparent differences in efficacy and safety profiles of either manufactured batches indicating the quality controllability and clinical consistence of this herb drug,” Dr. Sun said.
The findings are significant for patient care as a growing number of patients, particularly those 7 million with advanced chronic coronary artery disease, experience symptoms of angina refractory.
Dantonic herbs a modernized and industrialized botanical drug formula, with 2 active ingredients and Borneol as an absorption enhancer. Dantonic consists of extracts of Danshen (Radix Salviae Miltiorrhizae), also known as red sage, and Sanqi (Radix Notoginseng), with borneol in a capsule form.
The botanic drug is used for a variety of heart related issues, including circulation problems, brain attack, stroke, chest pain and other diseases, impacting the heart and blood vessels. Danshen appears to thin the blood by preventing platelet and blood clotting.
The Food and Drug Administration of China (CFDA) approved Dantonic as a prescription drug and OTC for the treatment of chronic stable angina pectoris in patient with coronary heart disease in 1993. Dantonic is currently approved in 26 countries for the treatment and prevention of chronic stable angina pectoris and other cardiovascular disease related conditions. More than 2 billion doses have been prescribed worldwide. Dantonic is coded as T89 in U.S. development. The study verified 22 years worth of worldwide clinical practices.
The Phase 3 clinical study was conducted during July 2012 to March 2016 at 137 clinical sites across the world, including Canada, Georgia, Mexico, the United States, the Russian Federation and Ukraine.
National health regulatory authorities in no less than 34 countries worldwide have approved Tasly’s pharmaceutical products.
Tasly Pharmaceuticals Inc. was founded in Rockville Maryland in 2006. Tasly Pharmaceuticals is pioneering the most aggressive paradigm shift in modern medicine scientifically evidence that the long-term practice of Innovative Chinese Medicine, healing the body with pure, natural herbs, is as effective as treating it with chemical and synthetic drug compounds.
